Lexeo Therapeutics, Inc. (LXEO) — Stock Score Summary

Lexeo Therapeutics, Inc. (LXEO) has a MoatMap StockRank of 6/100 based on Quality (32/100), Value (40/100), and Momentum (13/100) factor scores. The current signal is STRONG SELL. Lexeo Therapeutics is a clinical-stage gene therapy biotech. It has no commercialized products, no revenues, and high cash burn, failing the Terry Smith lens for quality compounders and the Buffett lens for predictable owner earnings.

Lexeo Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing therapies for genetically defined cardiovascular, CNS, and other rare diseases. It utilizes a proprietary AAV gene therapy platform to target specific genetic defects, aiming to deliver one-time corrective treatments. The company is a specialized biotech company innovating in the gene therapy space, focusing on precision medicine for serious and often debilitating conditions.

Key Financial Metrics

Price$4.24
Market Cap$399M
P/E (Forward)-3.91
Price/Book1.53
Return on Equity-54.8%
Return on Invested Capital-39.6%
Debt/Equity3.18
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-67M

Lexeo Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Lexeo Therapeutics, Inc.’s (LXEO) StockRank?
MoatMap’s StockRank for Lexeo Therapeutics, Inc. (LXEO) is 6/100, with a Strong Sell signal. It is a composite of Quality (32), Value (40), and Momentum (13) factor ranks across MoatMap’s 19,000+ stock universe.
Does Lexeo Therapeutics, Inc. have an economic moat?
Lexeo Therapeutics, Inc. (LXEO) has a Quality factor score of 32/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Lexeo Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Lexeo Therapeutics, Inc. (LXEO) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Lexeo Therapeutics, Inc. in?
Lexeo Therapeutics, Inc. (LXEO) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksLXEO deep dive reportAI ChampionsHow we score stocksSense-check another stock